Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
Số trang: 7
Loại file: pdf
Dung lượng: 447.03 KB
Lượt xem: 5
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Axitinib is a potent inhibitor of the vascular endothelial growth factor (VEGF) receptor family with clinical activity in patients with metastatic renal cell carcinoma (mRCC). Given this biochemical potency, the clinical activity of subsequent treatment with targeted therapies in patients progressing on axitinib is of interest.
Nội dung trích xuất từ tài liệu:
Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
Nội dung trích xuất từ tài liệu:
Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Renal cell carcinoma VEGF inhibitors Predictive biomarkers Adenosine triphosphateTài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 172 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 120 0 0 -
12 trang 94 0 0
-
19 trang 74 0 0
-
17 trang 64 0 0
-
9 trang 44 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 38 0 0 -
13 trang 38 0 0